疗效判定客观有效 EPOCH 临床试验 抢救性治疗 病例 FOXFIRE trial 降期治疗 meta分析 一线治疗的结果
返回首页

TARE 治疗结直肠癌肝转移的客观有效率

时间:2017-03-30 22:21来源:未知 作者:Mr.Editor
Sato et al. Radiology 2008;247:507-515 Sato KT1, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R.



Sato et al. Radiology 2008;247:507-515【1】




Outcome
CRC
N = 58
NET
N = 43
Others
All Patients
N = 147
CR 0 (0.0)   0 (0.0)  0 (0.0)  0 (0.0)
PR 3 (5.2)  9 (20.9) 3 (6.5) 15 (10.2)
SD  31 (53.4) 31 (72.1)   26 (56.5) 88 (59.9)
PD  24 (41.4)  3 (7.0) 17 (37.0)  44 (29.9)
Any Response
 34 (58.6) 
40 (93.0)  29 (63.0)  103 (70.1)
Benson et al. Eur J Cancer 2013;49:3122-3130【2】
   
 

mCRC Radioembolization
Autor 病例 材料 治疗目的 研究设计 CR PR SD AR PD
Medianes
Überleben
Lewandowski 2005 27/26 Glas Salvage Prospektiv 0 35 52 87  13   9.3
Lim 2005 32/32 Resin ≥2nd line Retrospektiv 0 31 28   59  41  n.a
Mancini 2006 35/35 Resin Salvage Prospektiv 0 12 76 88 13  n.a.
Kennedy 2006 208/208 Resin Salvage  Retrospektiv 0 36 55 91 10
Responder
10.5; Non-
Responder
4.5
Stubbs 2006 100/80 Resin Mixed Retrospektiv 1 73 20 94  6 11
Sato 2008 51/51 Glas Salvage Prospektiv  n.a. n.a. n.a. n.a. n.a. 15.2
Jakobs 2008  41/36 Resin Salvage Retrospektiv 0 19 70 89  11  10
Cianni 2009  41/41  Resin Salvage Retrospektiv  40 36 81 19 11.9
van Hazel 2009  25/23 Resin ≥2nd line Prospektiv  48  39  87 13 12.2
Mulcahy 2009  72/72 Glas Mixed Prospektiv 0 40 45  85  15 14.5
Cosimelli 2010  50/46 Resin Salvage Prospektiv 2 24 26 52 48  12.6
Evans 2010  140/n.a Resin Salvage  Retrospektiv  n.a.  n.a.  n.a.  n.a.  n.a.  7.9
Hendlisz 2010  46/44 Resin  Salvage RCT 0 10  80 90  10  10
Chua 2011 140/140 Resin Mixed Retrospektiv 1 31 31  63   37 9

 

1. Sato KT1, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology. 2008 May;247(2):507-15. doi:0.1148/radiol.2472062029. Epub 2008 Mar 18.


2. Benson AB 3rd1, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G, Cunningham J, Houghton B, Ross M, Memon K, Andrews J, Fleming CJ, Herman J, Nimeiri H, Lewandowski RJ, Salem R. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer. 2013 Oct;49(15):3122-30. doi: 10.1016/j.ejca.2013.05.012. Epub 2013 Jun 15.

Patients with liver metastases can be safely treated with 90Y microspheres. This study is the first to demonstrate technical and dose reproducibility of 90Y glass microspheres between centers in a prospective setting. Based on these promising data, three international, multicenter, randomised phase III studies in colorectal and hepatocellular carcinoma have been initiated.
 
Mulcahy MF, Lewandowski RJ, Ibrahim SM, Sato KT, Ryu RK, Atassi B, Newman S, Talamonti M, Omary RA, Benson A 3rd, Salem R. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009 May 1;115(9):1849-58. doi: 10.1002 /cncr.24224.

Y90 liver therapy appears to provide sustained disease stabilization with acceptable toxicity. Asymptomatic patients with preserved liver function at the time of Y90 appeared to benefit most from treatment. 
顶一下
(0)
0%
踩一下
(0)
0%
------分隔线----------------------------
  • 上一篇:没有了
  • 下一篇:没有了
推荐内容